TY - JOUR

T1 - € Barrier dysfunction in Atopic newBorns studY' (BABY)

T2 - Protocol of a Danish prospective birth cohort study

AU - Gerner, Trine

AU - Halling, Anne Sofie

AU - Rasmussen Rinnov, Maria

AU - Haarup Ravn, Nina

AU - Hjorslev Knudgaard, Mette

AU - Menné Bonefeld, Charlotte

AU - Ewertsen, Caroline

AU - Trautner, Simon

AU - Jakaša, Ivone

AU - Kezic, Sanja

AU - Skov, Lone

AU - Thyssen, Jacob P.

PY - 2020

Y1 - 2020

N2 - Introduction Skin barrier development and dysfunction in premature and mature newborns is important for the risk of atopic dermatitis (AD). Methods and analysis The Barrier dysfunction in Atopic newBorns studY (BABY) Cohort is a prospective birth cohort study of 150 preterm children (gestational age (GA) below 37+0) and 300 term children (GA 37+0 to 41+6). Skin barrier is assessed through transepidermal water loss, tape stripping, Raman-spectroscopy and microbiome sampling. Clinical examinations are done and DNA from buccal swabs is collected for genetic analyses. Thymus size is assessed by ultrasound examination. Information on pregnancy, delivery, parental exposures and diseases are collected, and structured telephone interviews are conducted at 18 and 24 months to assess exogenous exposures in the child and onset of AD. Hanifin and Rajka criteria as well as The UK Working Party's Diagnostic Criteria for Atopic Dermatitis are used to diagnose AD. Severity of AD is assessed using the Eczema Area and Severity Index (EASI) and Patient Oriented Eczema Measure (POEM). Ethics and dissemination The study is approved by the scientific Ethical Committee of the Capital Region (H-16042289 and H-16042294). Outcomes will be presented at national and international conferences and in peer-reviewed publications.

AB - Introduction Skin barrier development and dysfunction in premature and mature newborns is important for the risk of atopic dermatitis (AD). Methods and analysis The Barrier dysfunction in Atopic newBorns studY (BABY) Cohort is a prospective birth cohort study of 150 preterm children (gestational age (GA) below 37+0) and 300 term children (GA 37+0 to 41+6). Skin barrier is assessed through transepidermal water loss, tape stripping, Raman-spectroscopy and microbiome sampling. Clinical examinations are done and DNA from buccal swabs is collected for genetic analyses. Thymus size is assessed by ultrasound examination. Information on pregnancy, delivery, parental exposures and diseases are collected, and structured telephone interviews are conducted at 18 and 24 months to assess exogenous exposures in the child and onset of AD. Hanifin and Rajka criteria as well as The UK Working Party's Diagnostic Criteria for Atopic Dermatitis are used to diagnose AD. Severity of AD is assessed using the Eczema Area and Severity Index (EASI) and Patient Oriented Eczema Measure (POEM). Ethics and dissemination The study is approved by the scientific Ethical Committee of the Capital Region (H-16042289 and H-16042294). Outcomes will be presented at national and international conferences and in peer-reviewed publications.

KW - atopic dermatitis

KW - birth cohort

KW - preterm

KW - Raman

KW - skin barrier

KW - TEWL

U2 - 10.1136/bmjopen-2019-033801

DO - 10.1136/bmjopen-2019-033801

M3 - Journal article

C2 - 32660946

AN - SCOPUS:85088030888

VL - 10

JO - BMJ Open

JF - BMJ Open

SN - 2044-6055

IS - 7

M1 - e033801

ER -